An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?
Authors
Baker JDickman, A
Mason, S
Bickerstaff, M
Jackson, R
McArdle, A
Lawrence, I
Stephenson, F
Paton, Nina
Kirk, J
Waters, B
Ellershaw, J
Affiliation
Pharmacy Department, Royal Liverpool University Hospital, Prescot Street, LiverpoolIssue Date
2020
Metadata
Show full item recordAbstract
Background: Continuous subcutaneous infusions (CSCIs) are commonly used in the United Kingdom as a way of administering medication to patients requiring symptom control when the oral route is compromised. These infusions are typically administered over 24 h due to currently available safety data. The ability to deliver prescribed medication by CSCI over 48 h may have numerous benefits in both patient care and health service resource utilisation. This service evaluation aims to identify the frequency at which CSCI prescriptions are altered at NHS Acute Hospitals. Methods: Pharmacists or members of palliative care teams at seven acute NHS hospitals recorded anonymised prescription data relating to the drug combination(s), doses, diluent and compatibility of CSCIs containing two or more drugs on a daily basis for a minimum of 2 days, to a maximum of 7 days. Results: A total of 1301 prescriptions from 288 patients were recorded across the seven sites, yielding 584 discrete drug combinations. Of the 584 combinations, 91% (n = 533) included an opioid. The 10 most-common CSCI drug combinations represented 37% of the combinations recorded. Median duration of an unchanged CSCI prescription across all sites was 2 days. Conclusion: Data suggests medication delivered by CSCI over 48 h may be a viable option. Before a clinical feasibility study can be undertaken, a pharmacoeconomic assessment and robust chemical and microbiological stability data will be required, as will the assessment of the perceptions from clinical staff, patients and their families on the acceptability of such a change in practice. Keywords: CSCI; Palliative therapy; Subcutaneous infusions.Citation
Baker J, Dickman A, Mason S, Bickerstaff M, Jackson R, McArdle A, et al. An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions? BMC Palliat Care. 2020;19(1):99.Journal
Bmc Palliative CareDOI
10.1186/s12904-020-00611-3PubMed ID
32635902Additional Links
https://dx.doi.org/10.1186/s12904-020-00611-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1186/s12904-020-00611-3
Scopus Count
Collections
Related articles
- Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability.
- Authors: Dickman A, Bickerstaff M, Jackson R, Schneider J, Mason S, Ellershaw J
- Issue date: 2017 Mar 23
- The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review.
- Authors: Baker J, Dickman A, Mason S, Ellershaw J
- Issue date: 2018
- Compatibility of medication admixtures in continuous subcutaneous infusions: prioritizing laboratory testing for common combinations.
- Authors: Leong MCI, Michael N, Wojnar R
- Issue date: 2024 Sep 3
- Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center.
- Authors: Fürst P, Lundström S, Klepstad P, Strang P
- Issue date: 2020 Nov 10
- Continuous subcutaneous infusion: is community anticipatory prescribing and administration safe?
- Authors: Coyle S, Sinden R, Wignall-Coyle J, Benson S, Powell P, Monnery D
- Issue date: 2024 Jan 8